Clarient's net income for the second quarter of 2010 was $942,000, or $0.01 per diluted share, compared with net income of $29,000, or $0.00 per diluted share, for the same period of 2009.  Adjusted EBITDA for the 2010 second quarter was $3.3 million as compared to $2.3 million in the prior year period.    

As of June 30, 2010, Clarient's cash and cash equivalents totaled $9.6 million.  

Andrews concluded, "The results for the first half of 2010 are a testament to the commitment of all Clarient employees who have worked to improve systems, find efficiencies and better serve our physician partners and their patients. We anticipate maintaining this momentum into the second half of the year driven by continued success growing both new accounts and same-store sales.  We are also looking forward to accelerating the pace of new test introductions ??“ including our new breast cancer prognostic test Clarient Insight?® Dx Mammostrat?®.  The fact that the significant expected contributions from our exciting product pipeline are not included in our strong first half momentum is encouraging.  This strengthens our confidence in Clarient's ability to emerge as the leading molecular cancer diagnostics company, even in the face of the uncertainties that exist in the current market environment."

Company Outlook

Based on Clarient's current net revenue run rate, anticipated new product introductions and other market factors, Clarient expects net revenue for the full year 2010 to be within stated guidance of between $108 million to $115 million.  This range represents a year-over-year growth rate of between 18 percent and 25 percent from 2009 net revenue.  The Company also expects to report net income for the 2010 fiscal year.

SOURCE Clarient, Inc.